Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The goal of this (monocentric, randomised, placebo-controlled single-blinded; phase 2)
clinical trial is to test the hypothesis that DNase 1 administration leads to a reduction in
systemic immune response measured in patients after acute ischaemic stroke compared to
control treatment.
Participants will receive intravenous DNase 1 (500 µg/kg) or placebo (NaCl 0.9%) twice within
24±6 hours after symptom onset (last seen well). Blood samples will be taken at baseline, day
1 and 3. Personal visits will occur on baseline, day 1, 3 and discharge date. A telephone
interview will be conducted on day 30±3.
Phase:
Phase 2
Details
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Collaborators:
Centre for Clinical Trials University Hospital Regensburg Clinical Study Center and Safety Services LMU Hospital Institute for Laboratory Medicine LMU Hospital Pharmacy of University Hospital Erlangen